Baseline Characteristics of Patients in a Phase II NSCLC Trial, China 2022-2024

56 older and/or frail patients with stage III non-small-cell lung cancer (NSCLC) were enrolled in a phase II randomized trial between September 30, 2022 and April 30, 2024. The dataset, authored by Wei-Xiang Qi and shared on figshare, contains baseline characteristics for participants who were ineligible for concurrent chemoradiotherapy. The trial compared standard versus reduced intensity thoracic radiotherapy combined with sequential chemo-immunotherapy.

Use Cases

• Analyze baseline patient characteristics for a specific vulnerable NSCLC population based on the trial's inclusion criteria.
• Compare baseline demographics between treatment arms (standard vs. reduced radiotherapy) mentioned in the trial description.
• Support meta-analyses on radiotherapy intensity and outcomes in older/frail oncology patients based on the trial's endpoints.
• Study the feasibility of reduced radiotherapy combined with sequential chemo-immunotherapy as described in the trial conclusion.

Strengths

• Data originates from a registered phase II randomized clinical trial (NCT05557552), providing a structured research context.
• Includes results for key clinical endpoints: 1-year progression-free survival rates with 95% confidence intervals are provided for both treatment groups.
• Safety outcomes are quantified, reporting that 71.4% and 53.6% of patients experienced grade 3/4 adverse events in the standard and reduced RT groups, respectively.

Limitations

• The trial had a non-comparative design and a small sample size of 56 patients, limiting statistical power as noted in the description.
• Column-level documentation is absent; field semantics must be inferred after download from the XLS file.
• Row count is unknown, which may limit suitability assessment for specific analytical tasks.

Provenance

Source

figshare, authored by Wei-Xiang Qi.

Collection Method

Collected as part of a phase II randomized, open-label, two-cohort trial conducted at a tertiary hospital in China.

Time Range

Trial enrollment occurred between September 30, 2022 and April 30, 2024, with a median follow-up of 24 months.

Freshness

Last updated 2026-05-27 18:00:15; freshness should be verified.

Geography

The trial was conducted at a tertiary hospital in China.